SPHERE Uptravi® (SelexiPag): tHe usErs dRug rEgistry (SPHERE)

General Information Age Group Adults Status Closed Protocol Number AC-065A402 Background Information To develop and maintain a database of de-identified patient medical information and other related information in order to better assess and optimize outcomes for patients diagnosed with PAH and receiving treatment with Uptravi®. Age Group: Patients ≥ 18 years of age at time of Uptravi initiation. National Clinical Trial (NCT) identifier on clinicaltrials.gov: NCT03278002 Offered At Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Clinic, 3300 Gallows Road, Falls Church, VA 22042 Principal Investigator Oksana Shlobin, MD Eligibility Information Eligibility Information (brief) Signed patient ICF. Patients with PAH who either initiate Uptravi at the time of enrollment or have been receiving treatment with Uptravi and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and highest tolerated dose). Ineligibility Information Ineligibility information (brief) Patients previously exposed to Uptravi treatment during a clinical trial. Contact Information Contact Name Drew Venuto Contact Phone 703-776-6485 Contact Email Send Email Contact Information Contact Email Send Email